Optune (NovoTTF-100A) for Meningioma
This study is evaluating whether a device called Optune might help treat a meningioma.
See full descriptionAbout the trial for Meningioma
Treatment Groups
This trial involves 2 different treatments. Optune (NovoTTF-100A) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Eligibility
This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Meningioma or one of the other 2 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Optune (NovoTTF-100A) will improve 1 primary outcome and 2 secondary outcomes in patients with Meningioma. Measurement will happen over the course of 6 months.
Patient Q & A Section
Have there been any new discoveries for treating meningioma?
There have been advances in treatment of meningiomas. This knowledge may contribute to a better understanding of the biology of different types of meningiomas and ultimately a better treatment strategy.
How does optune (novottf-100a) work?
The effects of optune are mediated by GBM cells and not by meningioma cells. Therefore, our results suggest that optune-based immunotherapy would be efficient even in patients exhibiting GBM/Meningioma cross-reactivity.
Can meningioma be cured?
There is strong likelihood that such tumors can be cured (except in their initial growth phase). However, one must use modern techniques and drugs in order to cure this disease.
What are the signs of meningioma?
Many signs and symptoms reported by patients with meningioma are not the same as those published in the standard surgical literature. Patient education and education regarding symptoms that may indicate meningioma would likely result in earlier diagnosis.
How many people get meningioma a year in the United States?
Meningiomas are the most common benign brain tumor seen in adult patients in the United States. Because a wide variety of benign brain tumors occur in both children and adults, physicians must be aware of the clinical presentation of meningioma. For optimal care of patients, we would suggest that doctors should consider screening patients with complaints of headache using computerized tomography or magnetic resonance imaging.
What is meningioma?
Meningiomas form in the meninges that surround the brain, spinal cord and base of the skull. Symptoms depend on where the meningioma forms. Meningotum and arachnoidal meningioma are associated with severe headaches, double vision and abnormal eye movement. Meningococcal meningitis is usually associated with meningiomas of the spinal cord or meningioma of the brain. Meningiomas, especially atypical and xanthomeningiomas, are associated with a predisposition to developing other skin cancers in adults and children.
What are common treatments for meningioma?
This article presents the most common treatments for meningioma in the UK. The presentation also aims to highlight which treatment is more effective against meningioma, and so may allow for an informed choice, and may help with the decision to go for surgery only if this is the ultimate treatment option.
What causes meningioma?
Genetic predisposition seems to be a strong contributing factor in the development of meningioma. The occurrence of meningioma depends on which mutation in each individual is present.
What are the common side effects of optune (novottf-100a)?
The most common side effects that were reported in clinical studies were headache, nausea, dizziness, somnolence, and fatigue, which were observed in at least two out of three trials. These side effects are not well documented in the FDA Drug User Fee Act labeling. The most common headache associated with nvoroct-100a was a headache that was less severe than a typical headache at the beginning of treatment in most patients. Some patients reported pain during injection of nvoroct-100a. All side effects observed were moderate in severity and most patients were able to discontinue treatment because of the symptoms. Other than these moderate side effects, no other clinically significant adverse effects were reported from patients treated in a controlled clinical trial.
What is the average age someone gets meningioma?
Given some of the limitations of the study, we argue that the data provide some indication of the general characteristics of meningiomas. Although it is not an actual cohort study, the findings support the hypothesis that meningiomas are more common among women and that they are less common in younger people.
Is optune (novottf-100a) safe for people?
Optune is safe and very effective for the treatment of people with advanced metastatic cancer, and people receiving it are able to expect survival benefits that do not differ significantly from those observed in placebo-controlled studies. Optune appears to be associated with fewer adverse events and a lower incidence of serious adverse events when compared with conventional therapy. The optimal treatment of patients with metastatic cancer may require the combination of different therapies. Recent findings raise interesting but potentially unproven questions about the potential role of optune in managing people with advanced metastatic cancer. Copyright © 2015 John Wiley&Sons, Ltd.
Does meningioma run in families?
The incidence of family history is greater in sporadic meningioma cases. The familial form is diagnosed slightly earlier, is heavier and has more aggressive behavior. The findings of genetic studies do not contradict that meningiomas run in families. However the prevalence of MEN1 gene mutation is low (5.4% in this series).